Glycophos (Sodium Glycerophosphate Pentahydrate)

Glycophos is indicated for clinical situations where phosphate replenishment is needed. It is commonly employed in the following contexts:

• Treatment of hypophosphatemia in hospitalized patients.
• Inclusion in parenteral nutrition regimens to meet phosphate requirements.
• Electrolyte replacement during major surgery or critical illness.
• Support of bone mineralization in patients with prolonged phosphate deficiency.
• Adjunct therapy for metabolic disorders affecting phosphate metabolism.

Side effects of Glycophos vary in frequency and severity. They are generally related to the intravenous route and phosphate load.

Common

• Mild injection site discomfort or erythema.
• Transient nausea or vomiting.
• Temporary elevation of serum calcium levels.
• Mild headache.
• Low-grade fever.

Serious

• Hyperphosphatemia leading to calcium‑phosphate precipitation.
• Acute renal failure in susceptible individuals.
• Severe allergic reaction or anaphylaxis.
• Cardiac arrhythmias due to electrolyte imbalance.
• Metabolic acidosis in high‑dose scenarios.

When prescribing Glycophos, clinicians should consider several safety measures. Important precautions include:

• Assess baseline serum phosphate, calcium, and renal function before initiation.
• Adjust dose in patients with chronic kidney disease or impaired renal clearance.
• Monitor electrolytes frequently during therapy to avoid hyperphosphatemia.
• Use caution in patients with a history of hypersensitivity to phosphate preparations.
• Avoid rapid infusion rates that may precipitate calcium‑phosphate complexes.
• Discontinue if signs of severe allergic reaction develop.

Glycophos may interact with other medications or clinical conditions. Interaction considerations are:

Avoid

• Concurrent use of calcium supplements or calcium‑containing IV solutions without appropriate timing, due to risk of precipitation.
• High‑dose vitamin D therapy that can increase calcium absorption.

Use with caution

• Loop diuretics, which may alter calcium and phosphate balance.
• Antacids containing aluminum or magnesium, which can affect phosphate absorption.
• Blood‑pressure medications that influence renal perfusion.
• Drugs that affect renal function, such as aminoglycosides.
• Medications that prolong QT interval, as electrolyte shifts may exacerbate arrhythmias.